Navigation Links
Orchid Cellmark Appoints William J. Thomas Vice President and General Counsel
Date:11/20/2007

sitions in these segments reflect the company's accredited laboratories in the U.S. and U.K., its innovative genetic analysis technologies and expertise and the world-renowned Cellmark brand that has been associated with exceptional quality, reliability and customer service for nearly two decades. More information on Orchid Cellmark can be found at http://www.orchid.com.

All statements in this press release that are not historical are forward- looking statements within the meaning of the Private Securities Litigation Reform Act of 1995., including but not limited to Orchid Cellmark's belief that Mr. Thomas has the legal experience and skill set that will complement its management team well. Such statements are subject to the risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, Orchid Cellmark's ability to timely and successfully integrate ReliaGene's business, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of Orchid Cellmark's products and services, dependence on government funding and collaborations, regulatory approvals, competition, intellectual property of others, patent protection, litigation, the timing of release of federal funds, the timing and amount of contracts put up for bid, Orchid Cellmark's ability to timely and successfully initiate operational efficiencies, lower overhead and other remedial measures and Orchid Cellmark's continued relationship with DEFRA. These risks and other additional factors affecting these statements and Orchid Cellmark's business are discussed under the headings "Risks Related to Our Business" and "Risks Associated with Our Common Stock" in Orchid Cellmark's Annual Report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission, and in other filings made by Orchid Cellmark with the Secu
'/>"/>

SOURCE Orchid Cellmark Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Orchid Cellmark Reports Third Quarter 2007 Financial Results
2. WorldHeart Appoints David Pellone Chief Financial Officer
3. Novo Nordisk Appoints New Leader of North American Business
4. The American Liver Foundation Appoints Rick Smith, a Twenty-Year Veteran of The MS Society, as Chief Executive Officer
5. Millstone Medical Outsourcing Appoints Operations Manager of New Memphis, TN, Facility
6. China Holdings Appoints Ronald Shon Chairman of Advisory Board to Its Wholly-Owned Subsidiary China Power, Inc.
7. Resonant Medical Appoints New Vice President of Global Sales
8. Response Biomedical appoints S. Wayne Kay Chief Executive Officer
9. Stem Cell Therapy Disappoints Against Rare Kidney Ailment
10. EPI-Q Opens East Coast Office and Appoints Vice President-Business Development
11. President George W. Bush Appoints Susan G. Komen for the Cure Founder as Chief of Protocol
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/30/2014)... Sheridan Healthcare, Inc. , ... today announced that Adam Blomberg, MD, the national ... present at the Society for Healthcare Strategy & ... . The conference will be held October 12-15 ... a four-day conference that draws in more than ...
(Date:9/30/2014)... TN (PRWEB) September 30, 2014 ... of people throughout the United States and worldwide. ... Parkinson’s Disease are diagnosed each year, adding to ... with the disease. Approximately 400,000 people in the ... million worldwide. Add to these statistics the 2.4 ...
(Date:9/30/2014)... 2014 (HealthDay News) -- In books and movies, plots involving ... Now, new research suggests that the stereotype may be ... at data on more than 12,000 people from Finland. ... Turku, Finland, found that women typically preferred men who were ... throughout their lives. On the other hand, men tended ...
(Date:9/30/2014)... Bank, New Jersey (PRWEB) September 30, 2014 ... largest not-for-profit visiting nurse association—is pleased to announce that ... was honored with a NJBIZ “40 Under 40” ... of New Jersey’s most accomplished young businessmen and women ... who share a commitment to business growth, professional excellence ...
(Date:9/30/2014)... FL (PRWEB) September 30, 2014 ... company focused on the peripheral nerve repair market, announced ... during the American Society for Surgery of the ... week in Boston. , The ASSH ... the Utilization of Processed Nerve Allografts for Large Gap ...
Breaking Medicine News(10 mins):Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 2Health News:Sheridan Healthcare Anesthesiologist to Present at Society for Healthcare Strategy & Market Development Conference 3Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 2Health News:North American Seminars Introduces a New OT PT CME Course, Evidence Based Rehab Techniques for Parkinsons, Multiple Sclerosis and Peripheral Neuropathy 3Health News:When It Comes to Sex Partners, Men Prefer Younger Women: Study 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 2Health News:Visiting Nurse Association Health Group’s Dr. Steven Landers Honored with NJ BIZ “40 Under 40” Award 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 2Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 3Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 4Health News:AxoGen, Inc. Announces Presentation of Clinical Data for Avance® Nerve Graft at American Society for Surgery of the Hand 2014 Annual Meeting 5
... estimated 2 million women in the United States are ... the chronic and abnormal swelling of the arm, chest, ... treatment. While physicians will recommend proven techniques to manage ... that patients often won,t follow the recommendations, or they ...
... times more apt to develop the lung artery disorder, study ... four times more likely to develop a debilitating and potentially ... shows. , Pulmonary hypertension is caused by high blood pressure ... who suffer from the condition can become tired, dizzy and ...
... the question, do barriers to health care for ... tuberculosis? The study, published in the November 15, ... and now available online, suggests that undocumented immigrants ... than documented immigrants or U.S.-born patients, resulting in ...
... CEO John G. Schulte with Chairman ... Emile J. Geisenheimer., ... lawsuit on behalf of those who purchased Spectranetics Company,stock (Nasdaq: ... officer violated U.S. securities laws through illegal,marketing practices and false statements ...
... of their Regional PPO Network Area Pay ... ... Life Insurance Company,of America (Guardian), a leading provider of employee and ... Extended Access "travel network" for its health plan members.,Members utilizing health ...
... Pittsburgh-based Foundation,Radiology Group (FRG) signed a multi-year ... exclusive provider of diagnostic,imaging services effective December 31, ... in Coudersport Pennsylvania,and services multiple counties in north ... provides a wide range of primary and,secondary health ...
Cached Medicine News:Health News:MU study identifies patient strategies for managing symptoms of lymphedema 2Health News:MU study identifies patient strategies for managing symptoms of lymphedema 3Health News:Women at Higher Risk for Pulmonary Hypertension 2Health News:Health-care barriers for undocumented immigrants: Raising tuberculosis risk? 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 2Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 3Health News:Hagens Berman Sobol Shapiro: Class Action Filed Against Spectranetics 4Health News:Guardian Provides National Access to In-Network Medical Benefits 2Health News:Foundation Radiology Group Announces Multi-Year Deal with Charles Cole Memorial Hospital 2
(Date:9/30/2014)... 2014 Investor-Edge has initiated coverage ... IMMU ), Aeterna Zentaris Inc. (NASDAQ: AEZS ... Navidea Biopharmaceuticals Inc. (NYSE MKT: NAVB), and Exact Sciences ... can be accessed at: http://investor-edge.com/register . ... at 4,505.85, down 0.14%, the Dow Jones Industrial Average ...
(Date:9/30/2014)... , Sept. 30, 2014 It is evident from ... market is not performing upto expectations due to the lack ... asscoaited with the intake of omega-3 fatty acids. Among omega-3 ... the fish oil, attributed to the large vegetarian population in ... omega-3 polyunsaturated fatty acid (PUFAs) ingredients is in growth stage ...
(Date:9/30/2014)... , Sept. 30, 2014 CytRx Corporation ... and development company specializing in oncology, today announced ... trial evaluating aldoxorubicin compared to topotecan in subjects ... have relapsed or were refractory to prior chemotherapy. ... chemotherapeutic agent, doxorubicin. CytRx has received Orphan Drug ...
Breaking Medicine Technology:Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 2Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 3Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 4Watch List for Biotech Equities - Immunomedics, Aeterna Zentaris, OPKO Health, Navidea Biopharma, and Exact Sciences 5Omega-3 Polyunsaturated Fatty Acids (PUFAs) - An Indian Market Overview 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 2CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 3CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 4CytRx Initiates Global Phase 2b Clinical Trial of Aldoxorubicin for the Treatment of Relapsed/Refractory Small Cell Lung Cancer 5
... 2007 - Corgenix Medical,Corporation (OTC BB: CONX) ... data demonstrating a significant correlation,between serum levels ... disease. The data was presented at,the XXIst ... and,Hemostasis (ISTH) in Geneva, Switzerland., Data released ...
... of rHuPH20 with Humira Estimated to ... from 64% to 100%,-, SAN DIEGO, ... Inc. , a biopharmaceutical company developing ... that,final results of the Enhanze(TM) Technology ...
Cached Medicine Technology:Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 2Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 3Corgenix Reports New Clinical Data Correlating AtherOx Technology,With Vascular Disease 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 2Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 3Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 4Halozyme Therapeutics' Enhanze Technology Large Protein Molecule,Therapeutic Clinical Trial Results Presented at the 34th Annual,Meeting of the Controlled Release Society 5
... The AngioJet Xpeedior+120 Rheolytic Thrombectomy catheter is ... performance. Powerful saline jets create a low ... a vacuum effect. Thrombus is drawn into ... the jets, and removed from the body.,AngioJet ...
... combined with a stimulation lead ... Temporary Pacemaker can be used ... pacing is indicated. The device ... as well as diagnostic purposes ...
... a unique left ventricular assist device that helps ... being used in a small group of patients ... of an FDA-approved Feasibility Study. The patient can ... power source for minutes or hours. The Kantrowitz ...
... new Bicycle Ergometer ... braking system which ... reliable service while ... The hyperbolic workload ...
Medicine Products: